Skip to main content
. 2020 Apr 20;133(8):982–993. doi: 10.1097/CM9.0000000000000682

Figure 6.

Figure 6

Comparison between febuxostat and allopurinol in MACE with high CV risk (A), in CVE with high CV risk (B). CV: Cardiovascular; CVE: Cardiovascular events; MACE: Major adverse cardiovascular events.